Hemmel Amrania

Clinical Scientist Breast Oncology/Diagnostics Imperial College London/Charing Cross Hospital

Co-founder

Digistain· Summer 2021🇬🇧 London Area, United Kingdom

in LinkedIn

2021YC Summer 21 Batch· Y Combinator

Founder · since 2016

Company

Y Combinator

Role

YC Summer 21 Batch

Stage

—

no public source

Raised

—

no public source

Based

San Francisco Bay Area

Founder / co-founder — the company's markEmployee / research role

Source: LinkedIn work history

Profile coverage5 of 7 · missing posts, contact

Digistain

Pioneering Breast Cancer Diagnostics for a Healthier Tomorrow

Summer 2021

Experience

Career

Digistain
Chief Executive Officer · London, England, United Kingdom · 2020 – Present
2020
Imperial College London
Physicist - Cancer Diagnostics Development · 2009 – Present
2009
Y Combinator
YC Summer 21 Batch · San Francisco Bay Area · 2021
2021
SEMdoctor
Manager · London, England, United Kingdom · 2015 – 2021
2015
LightFi
Co-founder
Director of Business Development · London, United Kingdom · 2016 – 2019
2016
CHARING CROSS HOSPITAL
Clinical Research Associate · London, England, United Kingdom · 2015 – 2019
2015
Imperial Innovations Investment Management
Medical Technology Consultant · 2016
2016
Cancer Research UK (CRUK)
Clinical Research Associate · London, England, United Kingdom · 2005 – 2008
2005

Bio

Hemmel Amrania Ph.D, CEO has previously scaled several 7 figure businesses both in therapeutics and diagnostics. As a doctoral researcher he was awarded the Outstanding Research Prize at Imperial College London. He has also won several UK business awards including the Innovation & Entrepreneurship Challenge Imperial College and the Climate KIC Competition held by the Mayor of London. For Digistain he spear-headed the research out of the lab all the way through to clinical trials.